PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50325F80036Procurent of xofluza (baloxavir marboxil) 40mg — Genentech Usa, Inc

Genentech Usa, Inc holds $136.1M across 34 federal awards, concentrated at Department of Health and Human Services (HHS). The prior award was single-bid — competitive dynamics may favor a challenge. Recompete timing centers on the Sep 29, 2027 PoP end — agencies typically plan 12–18 months ahead.

Aspr/Orm-Sns

Awarding office

Genentech Usa, Inc

Recipient

Sep 29, 2027

PoP end

$37.5M

Obligated

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

Federal

Contract number75A50325F80036

Also listed as36F79723D0219-75A50325F80036

AgencyAspr/Orm-Sns

Awarding officeAspr/Orm-Sns

IncumbentGenentech Usa, Inc

UEISA85BMHCTXK5

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79723D0219

Place of performanceSOUTH SAN FRANCISCO, CA

PoP end (current)Sep 29, 2027

Obligated$37.5M

PROCURENT OF XOFLUZA (BALOXAVIR MARBOXIL) 40MG AND 80MG TABLETS is a federal award for Aspr/Orm-Sns held by Genentech Usa, Inc. Estimated value $75M ($37.5M obligated). Current period of performance ends Sep 29, 2027. Last award drew 1 bidder. Place of performance: SOUTH SAN FRANCISCO, CA.

PROCURENT OF XOFLUZA (BALOXAVIR MARBOXIL) 40MG AND 80MG TABLETS

Recompete timing

Public

● Expiring in 364 days

Current PoP ends Sep 29, 2027 (364 days remaining). Agencies typically plan 12–18 months ahead — at 12.0 months out, that window is already open. The buying decision is likely already in motion.

Bonuses end Sept 30

Want the durability read on 75A50325F80036? One Pursuit Analysis, $500, inside 48 business hours.

48 business hours
$500
Credits toward the Pack

Buy one Pursuit Analysis — $500

Incumbent footprint

Public record

Genentech Usa, Inc — $136.1M obligated across 34 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($136.1M) · all agencies

Department of Health and Human Services (HHS)$134.6M · 99%Department of Defense (DOD)$1.6M · 1%

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75A50325F80036?

75A50325F80036 (Procurent of xofluza (baloxavir marboxil) 40mg) is a Aspr/Orm-Sns award with an estimated value of $75M, currently held by Genentech Usa, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50325F80036?

Aspr/Orm-Sns awarded 75A50325F80036 to Genentech Usa, Inc.

Who is the incumbent on 75A50325F80036?

Genentech Usa, Inc is the incumbent with $136.1M across 34 related awards in SCOUT’s public footprint. The current period of performance ends Sep 29, 2027.

When does Genentech Usa, Inc’s 75A50325F80036 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 29, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on 75A50325F80036? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Buy one Pursuit Analysis — $500

Credits toward the Sprint Pack

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 20, 2026 · refreshed monthlyLatest procurement action Mar 17, 2026